Catálogo de publicaciones - revistas
Clinical Oncology
Resumen/Descripción – provisto por la editorial en inglés
Clinical Oncology is essential reading for all those with an active interest in the treatment of cancer. Its multidisciplinary approach allows readers to keep up-to-date with developments in their own as well as related fields.Each issue is carefully selected to provide a combination of high quality original research, informative editorials and state-of-the-art reviews. The Journal covers all aspects of the clinical management of cancer patients and its authors are drawn from leading international centres.
The Journal features papers on all types of malignant disease including pathology, diagnosis and therapy, including radiotherapy, and systemic treatment.
Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde sep. 1989 / hasta dic. 1994 | ScienceDirect |
Información
Tipo de recurso:
revistas
ISSN impreso
0936-6555
ISSN electrónico
1433-2981
Editor responsable
Elsevier
País de edición
Estados Unidos
Fecha de publicación
1989-
Cobertura temática
Tabla de contenidos
Comprehensive Health Risk Management after the Fukushima Nuclear Power Plant Accident
S. Yamashita; Hitoshi Ohto; Masafumi Abe; Koichi Tanigawa; Shunichi Yamashita; Kenji Kamiya; Seiji Yasumura; Mitsuaki Hosoya; Shinichi Suzuki; Akira Ohtsuru; Akira Sakai; Hiroaki Yabe; Masaharu Maeda; Keisei Fujimori; Tetsuo Ishikawa; Tetsuya Ohira; Tsuyoshi Watanabe; Hiroaki Satoh; Satoru Suzuki; Toshihiko Fukushima; Sanae Midorikawa; Hiromi Shimura; Takashi Matsuzuka; Hirofumi Mashiko; Aya Goto; Kenneth Nollet; Hideto Takahashi; Yoshisada Shibata; Makoto Miyazaki; Shiro Matsui; Seisho Tanaka
Palabras clave: Oncology; Radiology Nuclear Medicine and imaging.
Pp. 255-262
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working Group
Lia Gore; S. Percy Ivy; Frank M. Balis; Eric Rubin; Katherine Thornton; Martha Donoghue; Samantha Roberts; Suanna Bruinooge; Jennifer Ersek; Nancy Goodman; Caroline Schenkel; Gregory Reaman
<jats:sec><jats:title>Purpose</jats:title><jats:p> Children have historically been excluded from first-in-human studies of promising new cancer drugs and later phase adult clinical trials. Delays in evaluation may result in off-label use without dosing information as the only access to new drugs. A multistakeholder workshop was convened in May 2016 by ASCO and Friends of Cancer Research to identify opportunities for when it would be scientifically appropriate to expand trial eligibility to include children younger than age 18 years in first-in-human and other adult cancer clinical trials. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> This group convened experts from academia, government, and industry to review barriers to enrolling children and adolescents in oncology clinical trials. We evaluated the historical context, published literature, regulatory considerations, and myriad risks and benefits associated with lowering the age of enrollment on oncology clinical trials. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> We conclude that many of the historical concerns about including children early in oncology clinical trials do not apply in the current scientific and clinical environment of pediatric oncology and drug development; we provide specific recommendations for how the inclusion of children in early-phase investigational cancer drug trials might be accomplished. Automatic inclusion of pediatric patients is appropriate in early-phase trials that assess dose, safety, and pharmacokinetics in a variety of tumor types and later phase trials that assess efficacy in a specific disease that spans adult and pediatric populations. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Including children in appropriately designed adult clinical oncology trials is feasible and can be done in a way that enhances their access to these agents without compromising safety or development strategies. </jats:p></jats:sec>
Palabras clave: Cancer Research; Oncology.
Pp. 3781-3787